Sepehr Jamalkhani
A5070895986- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Cardiac Imaging and Diagnostics
- Lipoproteins and Cardiovascular Health
- Sepsis Diagnosis and Treatment
- Health, Environment, Cognitive Aging
- Acute Ischemic Stroke Management
- Cardiac tumors and thrombi
- Cardiac Structural Anomalies and Repair
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Diagnosis and Treatment of Venous Diseases
- Vitamin C and Antioxidants Research
- Coronary Interventions and Diagnostics
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Acute Myocardial Infarction Research
- Cardiovascular Effects of Exercise
- COVID-19 and Mental Health
- Viral Infections and Immunology Research
Shaheed Rajaei Cardiovascular Medical and Research Center
2021-2025
Iran University of Medical Sciences
2020-2025
Imam Khomeini Hospital
2023
Tehran University of Medical Sciences
2023
McMaster University
2021
Thrombosis and Atherosclerosis Research Institute
2021
Aalborg University
2020
Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis.To evaluate effects intermediate-dose vs standard-dose prophylactic anticoagulation among COVID-19 admitted intensive care unit (ICU).Multicenter randomized trial a 2 × factorial design performed 10 academic centers Iran comparing (first hypothesis) and statin therapy matching placebo (second hypothesis; not this article) adult ICU Patients...
Microvascular and macrovascular thrombotic events are among the hallmarks of coronavirus disease 2019 (COVID-19). Furthermore, exuberant immune response is considered an important driver pulmonary extrapulmonary manifestations COVID-19. The optimal management strategy to prevent thrombosis in critically-ill patients with COVID-19 remains unknown.
Abstract Background Thrombotic complications are considered among the main extrapulmonary manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration prophylactic antithrombotic therapy in these patients remain unknown. Methods This article reports final (90-day) results Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial (INSPIRATION) study. Patients COVID-19 admitted to...
Abstract Objective To assess the effect of statin treatment versus placebo on clinical outcomes in patients with covid-19 admitted to intensive care unit (ICU). Design INSPIRATION/INSPIRATION-S was a multicenter, randomized controlled trial 2×2 factorial design. Results for anticoagulation randomization have been reported previously. double blind atorvastatin are here. Setting 11 hospitals Iran. Participants Adults aged ≥18 years ICU. Intervention Atorvastatin 20 mg orally once daily...
Despite the low incidence of COVID myocarditis, its influence on outcomes is substantial. The pivotal role cardiac magnetic resonance (CMR) in diagnosing myocarditis considered to be associated with disease prognosis. primary objective this study was conduct a comparative analysis myocardial injury patterns, CMR pathologic features, outcomes, and their correlation findings COVID- non-COVID-related myocarditis. This historical cohort involved 124 patients diagnosed (COVID-19 or non-COVID-19),...
Air pollution is associated with excess thrombotic and cardiovascular events. However, clinical outcomes trials evaluating interventions to mitigate such adverse events in patients atherosclerotic diseases (ASCVD) are lacking. This a single-center, open-label, feasibility randomized controlled trial (RCT) conducted adult documented ASCVD. Participants were hybrid strategy consisting of an educational flashcard, cell phone text message alerts on polluted days stay indoors, use KN95 masks if...
Background In the INSPIRATION-S trial, atorvastatin versus placebo was associated with a nonsignificant 16% reduction in 30-day composite of venous/arterial thrombosis or death intensive care unit (ICU) patients COVID-19. Thrombo-inflammatory response coronavirus disease 2019 (COVID-19) may last beyond first 30 days. Methods This article reports effects 20 mg daily on 90-day clinical and functional outcomes from INSPIRATION-S, double-blind multicenter randomized trial adult ICU The main...
ABSTRACT Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across spectrum illness severity COVID-19. A variety antithrombotic agents, doses durations therapy being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients medical wards, critically-ill with This manuscript provides a...
Background: Pulmonary embolism (PE) is a major public health concern, with considerable mortality rate. In the present study, we have evaluated impact of registry implementation on PE management. Methods: single-center composed two distinct cohorts, (prospective arm-September 2015 to August 2018) patient management and survival, compared it same duration when no was implied (retrospective 2012 2015). Results: One hundred seventy 182 patients were recruited in prospective retrospective arms,...
Backgrounds: In the INSPIRATION-S trial, atorvastatin versus placebo was associated with a non-significant 16% reduction in 30-day composite of venous/arterial thrombosis or death ICU patients COVID-19. Thrombo-inflammatory response COVID-19 may last beyond first 30 days. Methods: This article reports effects 20 mg daily on 90-day clinical and functional outcomes from INSPIRATION-S, double-blind multicenter randomized trial adult The main outcome for this pre-specified study adjudicated...